Skip to content
Sign inOpen the app
Artwork for The Long Run with Luke Timmerman
The Long Run with Luke Timmerman · January 8 · 1 hr 26 min

Ep192: Kate Haviland on Following the Science to Precision Immunology

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

0:00-1:26:06
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

more episodes

All episodes